Step Up Innovation

Now in its acceleration phase, Teva continues to step up innovation by working on breakthrough treatments for diseases that are on the rise worldwide, such as inflammatory bowel disease (IBD), multiple system atrophy (MSA), asthma and celiac disease. The last two years have seen several new launches and positive results for treatments in clinical trials. At a recent strategy day presentation to industry professionals, Eric Hughes, Executive VP Global R&D and Chief Medical Officer, outlined how Teva is evolving from a world-class generics company into an innovative biopharma leader.

CEO perspective

Building a modern development engine

Eric Hughes, Teva’s Executive VP Global R&D and Chief Medical Officer, explains the transformation of Teva from a world-class generics company to a world-class biopharma company enabled by generics.

“It started about two and a half years ago, before the Pivot to Growth strategy was launched. We reorganized and created a modern drug development department at Teva, bringing in some great talent and accelerating, not only our early pipeline, but more importantly our late-stage pipeline. We did that by staying focused, using proven science, allocating capital strategically and using partners to maximize our programs and product portfolio.”

New launches: what’s next for Teva?

Teva is focused on research to provide potential new treatments for a range of therapeutic areas, including gastroenterology, respiratory diseases, immunology and movement disorders. These conditions have a high level of unmet patient need and some simply have no cure. Such as these:

Inflammatory bowel disease

A chronic inflammatory disease affecting the digestive system, IBD affects approximately 4.9 million people worldwide – and to date there isn’t a cure. A debilitating condition, symptoms include weight loss, diarrhea, abdominal pain, rectal bleeding, and fatigue, and its prevalence is increasing worldwide. Read more.

In partnership with Sanofi, Teva is developing a potential new treatment for IBD to address unmet patient needs. Currently undergoing clinical trial for UC and CD indications, initial results have been positive and suggest that this novel biologic may potentially treat many different types of indications.

Read more about the science behind the treatment

Multiple system atrophy

MSA is a rare, rapidly progressive, and serious neurological condition that is often confused with Parkinson’s disease. Treatment involves managing patient symptoms, there is currently no cure.

MSA typically appears in adults around the age of 60, affecting both men and women. Life expectancy, after diagnosis, is about 6-10 years. Read more.

Teva is collaborating with biotech innovators MODAG to explore treatment options for the condition, aimed at providing better health for MSA patients across the globe. An important task, as Dieter Schultewolter, Teva VP Global Medical Affairs Neuroscience, explains: “The consequences of neurological diseases affect so much more than the nervous system; they often turn the affected person’s life upside down. This feeds our relentless quest for ‘what’s next’ in innovative treatments.”

Read more about Teva’s work in neuroscience

Asthma

Affecting over 260 million people worldwide and causing hundreds of thousands of deaths every year, asthma is a chronic lung condition affecting the ability to breathe. It can lead to frequent hospital visits and missed school or workdays, impacting quality of life for patients and their loved ones. Read more about the condition.

Teva has decades of expertise in respiratory care and asthma is a critical focus issue, demonstrated in our extensive portfolio of both innovative and generic medications. Recent work includes a collaboration with biotechnology pioneers Biolojic Design to develop a potential new therapy for inflammatory diseases such as atopic dermatitis and asthma using computational biology and AI, illustrating our commitment to applying cutting-edge science to address unmet medical needs.

Celiac disease

Celiac disease is a serious autoimmune disease that causes inflammation to the small intestine when gluten is consumed. It is estimated to affect 1 in 100 people worldwide, but only about 30% are properly diagnosed.

Teva’s investigational treatment for the disease, designed to reduce intestinal inflammation and damage caused by gluten consumption in patients, has received Fast Track designation from the US Food and Drug Administration (FDA) and is currently in clinical trials. Fast Track is an FDA process designed to facilitate development and expedite the review of drugs to treat serious conditions and address unmet medical needs. Read more.

What does the future look like?

NPS-ALL-NP-01710 FEBRUARY 2026